Was thinking about the SARAH trial, and wondering if the data would increase the chances of public sector reimbursement in France. Being a public funding situation it will always be a big ask, but the data may well support HCC, especially the right hand source pts.
Trust the EU dudes are actively pursuing this in France.
I do hope that, if granted, it is not restricted by annual cap as in the UK.
Add to My Watchlist
What is My Watchlist?